Praxis Precision Medicines, Inc. PRAX R2KR3KPHARMA
Company Overview
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molecule inhibitor of T-type calcium channels that in NDA for the treatment of essential tremor; relutrigine, a small molecule, which is in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting the hyperexcitable state of sodium-channels in the brain that is in Phase 3 trial for the treatment of adjunctive focal epilepsy, as well as in Phase 2 trial for monotherapy focal epilepsy; and Elsunersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, which is in Phase 3 trial for the treatment of SCN2A-DEE. In addition, the company is developing product candidates in pre-clinical trial comprising PRAX-020 to treat KCNT1; PRAX-080 that targets PCDH19 mosaic expression disorders; PRAX-090 for targeting SYNGAP1 loss-of-function; and PRAX-100 that targets SCN2A LoF mutations. It has a cooperation and license agreement with RogCon Inc.; research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and research collaboration and license agreement to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide. The company was formerly known as EpiPM Therapeutics, Inc. and changed its name to Praxis Precision Medicines, Inc. in October 2016. Praxis Precision Medicines, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.08.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +617.25% |
| 6 Months: | +13.23% |
| 3 Months: | +38.51% |
| 1 Month: | -4.96% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.48 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRAX Praxis Precision Medicines, Inc. R2KR3KPHARMA | 351.81 | -26.27 | $9.81B | 0.00% | -37.15% | -38.86% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | - | 683.00K | 781.00K | 468.00K | - | 431.00K | 357.00K | 302.00K | - | 0 | 0 | 0 | - | - |
| Operating Income | -10.65M | -8.47M | -11.57M | -16.22M | - | -27.42M | -36.48M | -44.77M | - | -68.85M | -60.39M | -44.29M | - | -38.09M | -34.96M | -25.52M | - | -41.89M | -37.49M | -56.84M | - | -74.73M | -76.07M | -78.36M | -105.86M | -96.90M |
| Net Income | -10.61M | -8.33M | -11.57M | -16.22M | -25.71M | -27.37M | -36.40M | -44.70M | -58.58M | -68.72M | -60.19M | -43.95M | -41.17M | -37.45M | -34.31M | -24.63M | -26.88M | -39.55M | -32.68M | -51.91M | -58.68M | -69.30M | -71.13M | -73.93M | -92.56M | -83.72M |
| Diluted EPS | - | - | -8.28 | -12.10 | - | -0.71 | -0.88 | -1.00 | - | -1.51 | -1.32 | -0.96 | - | -10.58 | -7.38 | -2.72 | - | -2.84 | -1.74 | -2.75 | - | -3.29 | -3.31 | -3.36 | -3.20 | -2.87 |
| R&D Expense | 9.35M | 6.87M | 9.05M | 12.79M | - | 17.93M | 25.68M | 33.14M | - | 52.65M | 43.62M | 30.44M | - | 25.50M | 25.61M | 17.26M | - | 26.98M | 27.26M | 41.88M | - | 60.81M | 63.01M | 65.80M | 77.99M | 69.42M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 2.45M | 8.55M | 0 |
| Operating Income | -35.79M | -61.97M | -167.33M | -214.99M | -126.37M | -200.16M | -326.20M |
| Net Income | -35.51M | -61.82M | -167.06M | -214.03M | -123.28M | -182.82M | -303.27M |
| Diluted EPS | - | -7.86 | -3.94 | -69.65 | -18.69 | -10.21 | -13.48 |
| R&D Expense | 29.56M | 44.98M | 120.26M | 155.04M | 86.77M | 152.41M | 267.12M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 47.69M | - | - | - | 303.18M | - | - | - | 292.75M | - | - | - | 115.13M | - | - | - | 87.95M | - | - | - | 483.11M | 937.91M |
| Total Equity | -41.04M | -81.01M | -90.76M | -104.08M | -123.26M | 287.46M | 265.51M | 333.77M | 295.92M | 250.81M | 191.02M | 138.87M | 105.16M | 76.11M | 64.47M | 105.62M | 86.76M | 69.67M | 229.68M | 419.10M | 382.67M | 445.45M | 878.14M |
| Cash & Equivalents | - | 44.81M | - | - | - | 296.61M | - | - | - | 138.70M | - | - | - | 61.62M | - | - | - | 81.30M | - | - | - | 215.37M | 357.33M |
| Total Liabilities | - | 7.58M | - | - | - | 15.72M | - | - | - | 41.94M | - | - | - | 39.02M | - | - | - | 18.28M | - | - | - | 37.66M | 59.77M |
| Current Liabilities | - | 6.82M | - | - | - | 15.72M | - | - | - | 38.43M | - | - | - | 34.34M | - | - | - | 15.75M | - | - | - | 37.55M | 59.77M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -33.42M | -52.62M | -124.55M | -185.04M | -111.14M | -131.76M | -249.07M |
| Investing Cash Flow | -103.00K | 0 | -140.52M | 96.89M | 38.95M | -248.49M | -311.15M |
| Financing Cash Flow | 60.39M | 304.42M | 107.59M | 10.46M | 91.87M | 514.32M | 702.17M |
| Capital Expenditure | -103.00K | -0 | -1.05M | -444.00K | -50.00K | -0 | -56.00K |
| Free Cash Flow | -33.52M | -52.62M | -125.60M | -185.49M | -111.19M | -131.76M | -249.12M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -5,164.4% | -2,340.3% | - |
| Net Margin % | - | - | - | - | -5,037.9% | -2,137.5% | - |
| ROE % | 43.8% | -21.5% | -66.6% | -281.2% | -176.9% | -41.0% | -34.5% |
| ROCE % | -87.6% | -21.6% | -65.8% | -266.1% | -175.0% | -44.9% | -37.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jupiter Topco LLC | 12.25% | 3.42M | $1.18B |
| 2 | FMR, LLC | 8.30% | 2.32M | $798.75M |
| 3 | Blackrock Inc. | 8.21% | 2.29M | $790.37M |
| 4 | Perceptive Advisors Llc | 7.29% | 2.04M | $701.91M |
| 5 | Baker Bros. Advisors, LP | 6.28% | 1.75M | $604.42M |
| 6 | Orbis Allan Gray Ltd | 5.48% | 1.53M | $527.39M |
| 7 | Vanguard Portfolio Management LLC | 4.78% | 1.34M | $460.31M |
| 8 | Vanguard Capital Management LLC | 4.42% | 1.24M | $425.87M |
| 9 | State Street Corporation | 3.68% | 1.03M | $353.87M |
| 10 | Adage Capital Partners GP L.L.C. | 3.64% | 1.02M | $350.09M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRAX
Sixty-six new employees receive stock awards from Praxis. They vest over four years. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQS0c5bFRkWHoyTlNfSW44T3RERHJlTzRKd29tNXpXZWxjY1B2azFsZXhsaXhlLTE3bmQwc2h4NVJHNXRXTi1sQlU2V3NDTkxTSFBEN0EyZkZMM1ZuU0c3SjliTUZjWUpTc0hfbHBndjhRazRvTEVKT2J6U29yYlVXek1HUWFmUE8zX2xETF…
Praxis Precision Medicines (PRAX) Stock After Mixed POWER1 Trial Results How Does The Valuation Stack Up - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPb21aOVU4cUhncjFIb0JsVW5rR0s4dGNYYkNuY05hUzBlSWV3aDVOVXQ4b256eTl1R3c2UUlxeUFCZi1ad3FzUXhxbHFYT2FBb0g0QmVRZmZ5OXNad3dhN0xka3I2RGIwbVN0cndvTl9SSTRQaWtERjZRWGtORzhyS0gwZGN1MXNRQWRwd1…
PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOcl9vQ1ZQZnFrUDhXejlnSnpzZnZnSWNwRDZNUFpLcU1FcTVSbnpLdndwY1lDTkNkdnp3em5SRC1MMzlETU13VmFCMWZIQ3FoRDJpbUFQcWZ3LWlrOXFWbFpyeXRldi1PYVc4Z1c2cDNsT28wSDZMb2NWdW5YY2tHZnhJVWJ5SUZjWEcxMH…
(PRAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNbm5XN1QtUHNoSk80VU00b24wbGJ2MTV4eUpjSDhLdHNDZk5zOWJxb041Sk9TdlJ4M0s4czdLdjhVUWJreW1CVGVYMGJYZUxNTmlFSjRpRWJWLVo0YmVCbkJhYXMwR0FFUWgzakJYV3RJbWdNbURIeXd1WFczYWdtelQ2SFgtZ0VUN1NhUV…
PRAX Stock Price, Quote & News - Syfe
<a href="https://news.google.com/rss/articles/CBMiS0FVX3lxTE9jXzY1b242NDJIQm1yZTl4OW1rdl8yVS1XdTFmekd2a2taTTFNN3dNelFsMGY3UVVJYU95cjJLbHdVUFlQV0F5WDBRVQ?oc=5" target="_blank">PRAX Stock Price, Quote & News</a> <font color="#6f6f6…
PRAX - Praxis Precision Medicines Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1GRTk0cFhtNjl4MmViQkptdm55SGJXZ2xkVjh3RXNxNjlIOVNJVmN2QjNvLWNpUlp0cjdPQXhSS0s4OGY4ZWc?oc=5" target="_blank">PRAX - Praxis Precision Medicines Inc Stock Price and Quote</a> &nb…
PRAX — Frequently Asked Questions
What is the current share price of Praxis Precision Medicines, Inc. (PRAX)?
As of 2026-09-07 16:24 PDT, Praxis Precision Medicines, Inc. (PRAX) trades at $351.81 on NasdaqGS. Its 52-week range is $37.70 to $386.33.
What is the market capitalisation of PRAX?
Praxis Precision Medicines, Inc. (PRAX) has a market capitalisation of $9.81B on NasdaqGS.
What is the P/E ratio of PRAX?
PRAX trades at a trailing price-to-earnings (P/E) ratio of -26.27. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.13.
What is the return on equity (ROE) of PRAX?
PRAX has a return on equity (ROE) of -38.86%. Its return on capital employed (ROCE) is -37.15%.
Is PRAX a good stock to buy?
This page provides a data-driven analysis of Praxis Precision Medicines, Inc. (PRAX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.